MYCN and cancer: This suggests that DDX1 is sufficient to drive mTORC1 pathway activation in the context of MYCN amplification without affecting the oncogenic potential of neuroblastoma cells, which could generate the dependency on mTORC1 observed in cancer cells harboring DDX1-MYCN amplifications.